imatinib mesylate has been researched along with Orphan Diseases in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akram, M; Quraishi, AM; Saeed, S; Tahir, M | 1 |
| Imai, Y; Kario, K; Kubota, K; Shinozaki, T | 1 |
| Ehmke, N; Gopakumar, H; Harrison, S; Sharma, NR; Zelt, C | 1 |
| Alves, P; Bota, S; Constantino, C; Maia, R | 1 |
| Ashman, P; Cid Ruzafa, J; Desai, K; Khalid, JM; Maguire, A; Muston, D; Starczewska Amelio, JM; Tzivelekis, S | 1 |
| Kobayashi, H; Sugihara, K | 1 |
| Hebestreit, H; Kunzmann, S; Leu, T; Simon, HU | 1 |
| Albuquerque, C; Claro, I; Dias Pereira, A; Francisco, I; Lemos, MM; Limbert, M; Pereira da Silva, J; Santos, F; Vale Rodrigues, R | 1 |
| Schmidt, C | 1 |
| Alvarez-Twose, I; Escribano, L; González, P; Jara-Acevedo, M; Matito, A; Mollejo, M; Morgado, JM; Orfao, A; Sánchez-Muñoz, L | 1 |
2 review(s) available for imatinib mesylate and Orphan Diseases
| Article | Year |
|---|---|
Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Incidence; Indoles; Models, Statistical; Piperazines; Prevalence; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rare Diseases; Registries; Sunitinib; Treatment Failure; United Kingdom | 2014 |
[The Hypereosinophilic Syndromes in Childhood].
Topics: Antibodies, Monoclonal, Humanized; Child; Child, Preschool; Cytostatic Agents; Diagnosis, Differential; Drug Approval; Germany; Glucocorticoids; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunologic Factors; Infant; Interleukin-5; Protein-Tyrosine Kinases; Rare Diseases | 2015 |
8 other study(ies) available for imatinib mesylate and Orphan Diseases
| Article | Year |
|---|---|
Philadelphia Chromosome Positive de novo Acute Myeloid Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Rare Diseases; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2016 |
Imatinib dramatically alleviates pulmonary tumour thrombotic microangiopathy induced by gastric cancer.
Topics: Carcinoma, Signet Ring Cell; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Rare Diseases; Receptors, Platelet-Derived Growth Factor; Stomach Neoplasms; Thrombotic Microangiopathies; Tomography, X-Ray Computed | 2017 |
Gastric Gastrointestinal Stromal Tumors (GIST): a Case Series and Current State of the Art in the Workup and Treatment of This Rare Disease.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Female; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Rare Diseases; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2019 |
Hypereosinophilia and severe bone disease in an African child: an unexpected diagnosis.
Topics: Adrenal Cortex Hormones; Africa; Albendazole; Animals; Anthelmintics; Antiparasitic Agents; Bone Diseases; Child, Preschool; Drug Combinations; Female; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Ivermectin; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Rare Diseases; Receptor, Platelet-Derived Growth Factor alpha; Strongyloides stercoralis; Strongyloidiasis; Treatment Outcome | 2019 |
Intra-abdominal desmoid tumor after resection for gastrointestinal stromal tumor of the small intestine: case report.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Fibromatosis, Abdominal; Fibromatosis, Aggressive; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rare Diseases | 2014 |
A case of multiple gastrointestinal stromal tumors caused by a germline KIT gene mutation (p.Leu576Pro).
Topics: Adult; Antineoplastic Agents; Asthenia; Biopsy; DNA Mutational Analysis; Endoscopy, Gastrointestinal; Exons; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Intestine, Small; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Proto-Oncogene Proteins c-kit; Rare Diseases; Stomach; Tomography, X-Ray Computed; Young Adult | 2017 |
From genome to drugs: where do we stand?
Topics: Antineoplastic Agents; Benzamides; Drug Approval; Drug Design; Drug Industry; Drug Resistance, Neoplasm; Genome, Human; Genomics; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Neoplasms; Orphan Drug Production; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Rare Diseases; Sulfonamides; United States; United States Food and Drug Administration; Vemurafenib | 2011 |
Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzamides; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Mastocytosis, Systemic; Piperazines; Pyrimidines; Rare Diseases; Severity of Illness Index; Treatment Outcome | 2012 |